Semantic dementia; Dementia - semantic; Frontotemporal dementia; FTD; Arnold Pick disease; Pick disease; 3R tauopathy
People with FTD have abnormal substances (called tangles, Pick bodies, and Pick cells, and tau proteins) inside nerve cells in the damaged areas of the brain.
The exact cause of the abnormal substances is unknown. Many different abnormal genes have been found that can cause FTD. Some cases of FTD are passed down through families.
FTD is rare. It can occur in people as young as 20. But it usually begins between ages 40 and 60. The average age at which it begins is 54.
The disease gets worse slowly. Tissues in parts of the brain shrink over time. Symptoms such as behavior changes, speech difficulty, and problems thinking occur slowly and get worse.
Early personality changes can help doctors tell FTD apart from Alzheimer disease. (Memory loss is often the main, and earliest, symptom of Alzheimer disease.)
People with FTD tend to behave the wrong way in different social settings. The changes in behavior continue to get worse and are often one of the most disturbing symptoms of the disease. Some persons have more difficulty with decision-making, complex tasks, or language (trouble finding or understanding words or writing).
General symptoms include:
NERVOUS SYSTEM PROBLEMS
The health care provider will ask about the medical history and symptoms.
Tests may be ordered to help rule out other causes of dementia, including dementia due to metabolic causes. FTD is diagnosed based on symptoms and results of tests, including:
A brain biopsy is the only test that can confirm the diagnosis.
There is no specific treatment for FTD. Medicines may help manage mood swings.
Sometimes, people with FTD take the same medicines used to treat other types of dementia.
In some cases, stopping or changing medicines that worsen confusion or that are not needed can improve thinking and other mental functions. Medicines include:
It is important to treat any disorders that can cause confusion. These include:
Medicines may be needed to control aggressive, dangerous, or agitated behaviors.
Behavior modification can help some people control unacceptable or dangerous behaviors. This consists of rewarding appropriate or positive behaviors and ignoring inappropriate behaviors (when it is safe to do so).
Talk therapy (psychotherapy) does not always work. This is because it can cause further confusion or disorientation.
Reality orientation, which reinforces environmental and other cues, may help reduce disorientation.
Depending on the symptoms and severity of the disease, monitoring and help with personal hygiene and self-care may be needed. Eventually, there may be a need for 24-hour care and monitoring at home or in a special facility. Family counseling can help the person cope with the changes needed for home care.
Care may include:
People with FTD and their family may need to seek legal advice early in the course of the disorder. Advance care directive, power of attorney, and other legal actions can make it easier to make decisions regarding the care of the person with FTD.
You can ease the stress of FTD by joining a support group. Sharing with others who have common experiences and problems can help you not feel alone. More information and support for people with FTD and their families can be found at:
The Association for Frontotemporal Degeneration -- www.theaftd.org/get-involved/in-your-region/
The disorder quickly and steadily becomes worse. The person becomes totally disabled early in the course of the disease.
FTD commonly causes death within 8 to 10 years, usually from infection, or sometimes because body systems fail.
Call your provider or go to the emergency room if mental function gets worse.
There is no known prevention.
Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682. PMID: 26595641 pubmed.ncbi.nlm.nih.gov/26595641/.
Peterson R, Graff-Radford J. Alzheimer disease and other dementias. In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL, eds. Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, PA: Elsevier; 2016:chap 95.BACK TO TOP
Review Date: 2/4/2020
Reviewed By: Amit M. Shelat, DO, FACP, FAAN, Attending Neurologist and Assistant Professor of Clinical Neurology, Stony Brook University School of Medicine, Stony Brook, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.